4,4'-di(benzoylthiocarbamoylamino)diphenylsulfone | 162781-16-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4,4'-di(benzoylthiocarbamoylamino)diphenylsulfone
• 英文别名: N-[[4-[4-(benzoylcarbamothioylamino)phenyl]sulfonylphenyl]carbamothioyl]benzamide
• CAS: 162781-16-0
• 化学式: C₂₈H₂₂N₄O₄S₃
• 分子量: 574.705
• InChiKey: BGUPIHQRGONFDU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  39
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  189
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  苯甲酰基异硫氰酸酯 、 氨苯砜 以 乙酸乙酯 、 丙酮 为溶剂， 以90.5%的产率得到4,4'-di(benzoylthiocarbamoylamino)diphenylsulfone
  参考文献：
  名称：

  Dimerized thiourea derivatives near-infared absorbents comprising the

  摘要：

  通过加热式1或式2的二聚硫脲衍生物和铜化合物，获得近红外吸收剂：##STR1## 该近红外吸收剂用于制备在近红外区域具有广泛吸收的近红外吸收树脂材料，且该吸收剂在树脂的成型温度下基本不分解。二聚硫脲衍生物的典型例子包括4,4'-二(苄基硫代氨基甲酰基)氨基二苯甲烷、4,4'-二(苄基硫代氨基甲酰基)氨基二苯基六氟丙烷和1,4'-二(二苯甲酰基硫代氨基甲酰基氨基)-2,5-二甲基苯，铜化合物的典型例子包括硬脂酸铜和β-丙烯酰氧基丙基氢邻苯二甲酸铜。

  公开号：

  US05723075A1

文献信息

• Dimerized thiourea derivatives, near-infrared absorbents comprising the same, and heat wave shielding materials comprising the same
  申请人：NIPPON PAPER INDUSTRIES CO., LTD.

  公开号：EP0611754A1

  公开（公告）日：1994-08-24

  A composition which comprises a thiourea derivative of Formula [1] or [2]: and a copper compound, may be used to prepare a near-infrared resin material which has a wide absorption in the near-infrared region. Typical examples of the dimerized thiourea derivative are 4,4'-di(benzylthiocarbamoyl)-aminodiphenylmethane, 4,4'-di(benzylthiocarbamoyl)-aminodiphenylhexafluo- ropropane, and 1,4'-di(dibenzoylthiocarbamoylamino)-2,5-dimethylbenzene and typical examples of the copper compound are copper stearate and copper β-acryloyloxypropylhydrogenphthalate.

  一种由式[1]或[2]的硫脲衍生物组成的组合物： 和铜化合物组成的组合物，可用于制备在近红外区域具有宽吸收率的近红外树脂材料。二聚化硫脲衍生物的典型例子有 4,4'-二（苄基硫代氨基甲酰基）-氨基二苯基甲烷、4,4'-二（苄基硫代氨基甲酰基）-氨基二苯基六氟丙烷和 1,4'-二（二苯甲酰基硫代氨基甲酰基氨基）-2,5-二甲基苯，铜化合物的典型例子有硬脂酸铜和β-丙烯酰氧基丙基氢邻苯二甲酸铜。
• Pharmaceutical Compositions For and Methods of Inhibiting Hcv
  申请人：Huang Mingjun

  公开号：US20080207760A1

  公开（公告）日：2008-08-28

  The present invention relates generally to replicase complex defect inducers and pharmaceutical compositions containing such inducers. Methods of developing mutants that are resistant to replicase complex defect inducers are also provided. Further included are mutants that can be used in screening for replicase complex defect inducers. Methods of screening test compounds for the ability to induce the formation of replicase complex defects are also described. Also included are methods of inhibition of HCV replication by replicase complex defect inducers.
• US5723075A
  申请人：——

  公开号：US5723075A

  公开（公告）日：1998-03-03